DGX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DGX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Quest Diagnostics's share price is $138.42. Quest Diagnostics's Owner Earnings per Share (TTM) ended in Mar. 2024 was $6.81. It's Price-to-Owner-Earnings for today is 20.33.
The historical rank and industry rank for Quest Diagnostics's Price-to-Owner-Earnings or its related term are showing as below:
During the past 13 years, the highest Price-to-Owner-Earnings of Quest Diagnostics was 36.21. The lowest was 6.92. And the median was 16.16.
As of today (2024-05-13), Quest Diagnostics's share price is $138.42. Quest Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $7.43. Therefore, Quest Diagnostics's PE Ratio for today is 18.63.
As of today (2024-05-13), Quest Diagnostics's share price is $138.42. Quest Diagnostics's EPS without NRI for the trailing twelve months (TTM) ended in was $8.13. Therefore, Quest Diagnostics's PE Ratio without NRI for today is 17.03.
During the past 13 years, Quest Diagnostics's highest PE Ratio without NRI was 23.89. The lowest was 7.82. And the median was 17.67.
The historical data trend for Quest Diagnostics's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Price-to-Owner-Earnings | Get a 7-Day Free Trial | 15.47 | 10.27 | 10.31 | 15.93 | 21.47 |
Quest Diagnostics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Owner-Earnings | Get a 7-Day Free Trial | 21.86 | 19.92 | 27.53 | 21.47 | 19.55 |
For the Diagnostics & Research subindustry, Quest Diagnostics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Price-to-Owner-Earnings falls into.
In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Quest Diagnostics's Price-to-Owner-Earnings for today is calculated as
Price-to-Owner-Earnings | = | Share Price | / | Owner Earnings per Share (TTM) |
= | 138.42 | / | 6.81 | |
= | 20.33 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (NYSE:DGX) Price-to-Owner-Earnings Explanation
For how to get Owner Earnings per Share (TTM), please click.
Thank you for viewing the detailed overview of Quest Diagnostics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.
Luis Diaz | director | C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138 |
Michael E Prevoznik | officer: Corp VP, Legal & Compliance | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Catherine T. Doherty | officer: SVP, Physician Services Bus. | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Timothy M Ring | director | C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974 |
Mark E Delaney | officer: SVP & Chief Commercial Officer | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Mark A Gardner | officer: SVP of Molecular Gen & Oncol | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Patrick Plewman | officer: SVP for Diagnostic Services | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Karthik Kuppusamy | officer: SVP, Clinical Solutions | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094 |
Michael J Deppe | officer: VP, Corp. Controller & CAO | 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094 |
Samer Abdul Samad | officer: Executive Vice President & CFO | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Stephen H Rusckowski | director, officer: President and CEO | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Tracey Doi | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Gail R Wilensky | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Mark Guinan | officer: Senior Vice President & CFO | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Daniel Stanzione | director | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.